Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia.

ABSTRACT:

Background

The aim of this study was to assess whether minimal residual disease (MRD) at the end of induction front-line treatment can serve as a surrogate endpoint for event-free survival (EFS) in childhood B-lineage acute lymphoblastic leukemia.

Methods

The analysis was based on individual data of 4830 patients from two large phase III trials that asked a randomized question on the effect of different corticosteroids (dexamethasone vs prednisone) during induction chemotherapy on EFS. The association between MRD classified in three ordered categories [negative = 0, low positive = (>0 and <5 × 10^-4), and positive = (≥5 × 10^-4)] and EFS at the individual and trial levels was evaluated with the meta-analytic approach based on the Plackett copula model. Ce

SUBMITTER: Galimberti S 

PROVIDER: S-EPMC6649800 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature